NGM · —

CLYM (CLYM) Stock

$14.00 +0.00% NGM: CLYM —

Valuation

MetricValue
Price$14.00
Market Cap$801.68M
P/E Ratio-11.77
P/B Ratio4.42
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$14.34
52-Week Low$1.17
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-37.50%
ROA-35.71%
ROCE-42.24%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio15.14

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-36.0M$-45.0M$-40.0M$-82.0M$-68.0M
Net Profit$-47.0M$-45.0M$-35.0M$-74.0M$-60.0M
EPS$-4.24$-1.72$-1.30$-1.53$-0.88
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$173.0M$135.0M$110.0M$217.0M$168.0M
Total Liabilities$6.0M$6.0M$3.0M$5.0M$7.0M
Cash$47.0M$44.0M$93.0M$87.0M$36.0M
Borrowings$0$0$0$1.0M$1.0M

Latest News

Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? Zacks · Jul 8, 2026 Climb Bio Insider Sold Shares Worth $406,979, According to a Recent SEC Filing MT Newswires · Jul 1, 2026 Climb Bio Reports Encouraging Phase 1b Results for Budoprutug in ITP MT Newswires · Jun 11, 2026 Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 GlobeNewswire · Jun 11, 2026 Guggenheim Initiates Climb Bio at Buy With $35 Price Target MT Newswires · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-36.0M$-37.0M$-21.0M$-16.0M$-54.0M
Investing Cash Flow$-115.0M$34.0M$69.0M$-121.0M$3.0M
Financing Cash Flow$0$0$0$11.0M$0
Net Cash Flow$26.0M$-3.0M$50.0M$-6.0M$-52.0M
Free Cash Flow$-36.0M$-37.0M$-21.0M$-16.0M$-55.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-7.22%
Quick Ratio27.86
Interest Coverage—
Return 1Y762.16%
Return 3Y340.00%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOS $2.27 -0.66% -1.17 $163.60M 0.00%
ACTU $1.09 -5.22% -2.73 $26.08M 0.00%
AGENAgenus Inc. $6.06 +1.34% 3.46 $252.35M 0.00%
ANIX $3.48 -1.14% -8.00 $118.40M 0.00%
ENTX $2.87 +1.77% -4.96 $141.46M 0.00%

About CLYM

CLYM is led by CEO Aoife Brennan BCh MMSc, employs 17 people, headquartered in US, publicly traded since 2021.

CLYM stock trades at $14.00 with a market capitalization of $801.68M. The stock is valued at a price-to-earnings (P/E) ratio of -11.77, price-to-book of 4.42, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.17 and $14.34, and currently trades 2.4% below its 52-week high.

On profitability, CLYM generates a return on equity (ROE) of -37.50%, return on capital employed of -42.24%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related — Stocks

BNY — $152.52 -2.54% CIEN — $412.39 +2.14% CBRS — $188.61 -5.28% HEI.A AIRCRAFT ENGINES & ENGINE PARTS $216.35 +0.00% LEN.B GENERAL BLDG CONTRACTORS - RESIDENTIAL BLDGS $80.32 +0.00% WSO.B WHOLESALE-HARDWARE & PLUMBING & HEATING EQUIPMENT & SUPPLIES $453.37 +0.00% MKC.V MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS $51.78 +0.00% MOG.B MISC INDUSTRIAL & COMMERCIAL MACHINERY & EQUIPMENT $322.00 +0.00% MOG.A MISC INDUSTRIAL & COMMERCIAL MACHINERY & EQUIPMENT $307.91 +0.00% UHAL.B SERVICES-AUTO RENTAL & LEASING (NO DRIVERS) $45.71 +0.00% TAP.A MALT BEVERAGES $47.89 +0.00% VSXY — $88.68 +0.50%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Screens featuring this stock

High ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides